Free Trial
NASDAQ:MURA

Mural Oncology 12/14/2023 Earnings Report

Mural Oncology logo
$2.54 -0.10 (-3.79%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$2.55 +0.01 (+0.24%)
As of 05/5/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology EPS Results

Actual EPS
-$3.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mural Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mural Oncology Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Mural Oncology's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Mural Oncology Earnings Headlines

BlackRock discloses stake in Mural Oncology
Goldman Sachs discloses stake in Mural Oncology
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
FORM 8.1(a) & (b) - Mural Oncology plc
See More Mural Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email.

About Mural Oncology

Mural Oncology (NASDAQ:MURA), a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

View Mural Oncology Profile

More Earnings Resources from MarketBeat